Your browser doesn't support javascript.
loading
Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study.
Ge, Li-Ping; Liu, Xi-Yu; Xiao, Yi; Gou, Zong-Chao; Zhao, Shen; Jiang, Yi-Zhou; Di, Gen-Hong.
Affiliation
  • Ge LP; Department of Breast Surgery, Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, yizhoujiang@fudan.edu.cn; dgh_2015@126.com.
  • Liu XY; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China, yizhoujiang@fudan.edu.cn; dgh_2015@126.com.
  • Xiao Y; Department of Breast Surgery, Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, yizhoujiang@fudan.edu.cn; dgh_2015@126.com.
  • Gou ZC; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China, yizhoujiang@fudan.edu.cn; dgh_2015@126.com.
  • Zhao S; Department of Breast Surgery, Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, yizhoujiang@fudan.edu.cn; dgh_2015@126.com.
  • Jiang YZ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China, yizhoujiang@fudan.edu.cn; dgh_2015@126.com.
  • Di GH; Department of Breast Surgery, Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, yizhoujiang@fudan.edu.cn; dgh_2015@126.com.
Cancer Manag Res ; 10: 4381-4391, 2018.
Article de En | MEDLINE | ID: mdl-30349371
ABSTRACT

BACKGROUND:

Occult breast cancer (OBC) is a rare type of breast cancer that has not been well studied. The clinicopathological characteristics and treatment recommendations for OBC are based on a limited number of retrospective studies and thus remain controversial. PATIENTS AND

METHODS:

We identified 479 OBC patients and 115,739 non-OBC patients from 2004 to 2014 in and the Surveillance, Epidemiology, and End Results (SEER) database. The clinicopathological characteristics and survival outcomes were compared between OBC and non-OBC patients. We used the propensity score 11 matching analysis to evaluate OBC vs non-OBC comparison using balanced groups with respect to the observed covariates. We further divided the OBC population into four groups based on different treatment strategies. Univariable and multivariable analyses were used to calculate and compare the four treatment outcomes within the OBC population.

RESULTS:

OBC patients were older, exhibited a more advanced stage, a higher rate of negative estrogen receptor and progesterone receptor status, a higher rate of HER2-positive status, and a higher rate of ≥10 positive lymph nodes, and were less likely to undergo surgical treatment than non-OBC patients. After adjustments for clinicopathological factors, the OBC patients exhibited a significantly better survival than the non-OBC patients (P<0.001). This result was confirmed in a 11 matched case-control analysis. Within the four OBC treatment groups, we observed no difference in survival among the mastectomy group, the breast-conserving surgery (BCS) group, and the axillary lymph node dissection (ALND)-only group. The multivariable analysis revealed that the sentinel lymph node dissection-only group had the worst prognosis (P<0.001).

Conclusion:

OBC has unique clinicopathological characteristics and a favorable prognosis compared with non-OBC. BCS plus ALND and radiotherapy showed a survival benefit that was similar to that of mastectomy for OBC patients.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline / Observational_studies / Prognostic_studies Langue: En Journal: Cancer Manag Res Année: 2018 Type de document: Article Pays de publication: NEW ZEALAND / NOVA ZELÂNDIA / NUEVA ZELANDA / NZ

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline / Observational_studies / Prognostic_studies Langue: En Journal: Cancer Manag Res Année: 2018 Type de document: Article Pays de publication: NEW ZEALAND / NOVA ZELÂNDIA / NUEVA ZELANDA / NZ